Bedrijfsoverzicht
Iovance Biotherapeutics, Inc. is a commercial-stage biopharmaceutical entity dedicated to the development and commercialization of cell therapies utilizing autologous tumor-infiltrating lymphocytes for the treatment of metastatic melanoma and other solid tumor cancers across the United States and internationally. The company operates within the broader Healthcare sector, specifically functioning in the Biotechnology industry, which distinguishes it from traditional pharmaceutical firms through its focus on advanced cellular medicine and proprietary therapeutic platforms. As of the latest reporting period, the organization employs 975 individuals and maintains a market capitalization of $1.52 billion, while generating annual revenue of $263.50 million. These valuation and revenue figures indicate that the company has established a significant presence in the oncology landscape, positioning it as a notable player within the biotechnology market that is generating substantial top-line growth despite being in a capital-intensive phase of commercial expansion.
Financiële gezondheid
Iovance Biotherapeutics, Inc. reported a trailing twelve-month revenue of $263.50 million, yet it recorded a net income of $-390,977,984 and an EBITDA of $-362,273,984, revealing a substantial gap between top-line sales and profitability that highlights the intense cost structure inherent in commercial-stage biotechnology development and commercialization. The company's free cash flow stood at $-162,422,128, indicating that the organization is currently burning cash to fund its operations and growth initiatives, which limits immediate financial flexibility but is typical for firms investing heavily in R&D and market penetration. Profitability metrics further illustrate this financial reality, with a gross margin of 34.3% suggesting moderate efficiency in production, contrasted by a negative operating margin of -84.7% and a profit margin of -148.4% that underscore the heavy overhead costs and research expenses consuming the majority of operating income. Regarding liquidity and leverage, the company holds $296.98 million in cash against $49.44 million in debt, resulting in a debt-to-equity ratio of 7.08 which suggests a leveraged balance sheet reliant on equity financing rather than debt service. Despite the leverage, the current ratio of 3.20 indicates a robust short-term liquidity position, as the firm holds more than three times its current liabilities in assets. The return on equity of -55.5% and return on assets of -27.3% reveal that management is currently deploying capital to generate negative returns on the books, a common scenario for growth-stage biotechs prioritizing long-term asset deployment over immediate shareholder yield.
Waarderingsbeoordeling
Valuation metrics for Iovance Biotherapeutics, Inc. reflect its status as a pre-profitability entity, with a trailing P/E ratio of N/A and a forward P/E of -15.63, implying that the market is pricing the stock based on future earnings expectations that have not yet materialized in historical data. The price-to-book ratio stands at 2.18, indicating that the market values the company at more than double its book value, which suggests a premium assigned to its intellectual property, pipeline potential, and growth prospects relative to its tangible net assets. Alternative valuation measures such as a price-to-sales ratio of 5.78 and an EV/EBITDA of -3.52 provide further context, showing that the market is willing to pay a significant multiple of sales despite the negative earnings, a standard practice in evaluating high-growth biotechnology companies where revenue quality is the primary valuation driver. In terms of trading range, the stock has a 52-week high of $5.63 and a 52-week low of $1.64, meaning the current price sits at a specific point within this volatility range that reflects recent market sentiment toward the company's clinical progress. The beta of 0.76 indicates that the stock exhibits lower volatility relative to the broader market, moving less aggressively than the overall index, which may offer some stability to investors seeking exposure to biotechnology with reduced short-term price swings compared to high-beta peers.
Growth & Income
Revenue growth for Iovance Biotherapeutics, Inc. reached 17.7% year-over-year, while earnings growth is listed as N/A due to the company's continued net losses, implying that top-line expansion is occurring independently of immediate profitability and that earnings are not yet growing faster than revenue as the firm scales. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which signifies that all generated earnings are retained to fund operations and strategic growth initiatives rather than being distributed to shareholders. This reinvestment strategy is characteristic of the biotechnology sector, where capital is directed toward clinical trials, manufacturing scale-up, and commercial expansion to achieve future profitability. The overall growth and income profile of Iovance Biotherapeutics, Inc. is defined by strong top-line momentum without current income distribution, reflecting a corporate strategy focused on long-term value creation through the successful commercialization of its cell therapy platform.